Microbubble‑Enhanced Focused Ultrasound with Temozolomide Shows Feasibility and Promising Survival in High‑Grade Glioma — Phase 1/2 Multicentre Results
A multicentre phase 1/2 trial reports that MRI‑guided microbubble‑enhanced transcranial focused ultrasound (MB‑FUS) can safely open the blood–brain barrier and be combined with standard adjuvant temozolomide in high‑grade glioma, with median overall survival 31.3 months and feasibility for non‑invasive plasma biomarker monitoring.